Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine versus lopinavir/ritonavir for mild to moderate COVID-19
ChiCTR2000029760Phase 4Suspended
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Time to clinical recovery. Started Feb 2020; status: suspended.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029760.